These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21672696)

  • 1. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
    Keene DL; Legare C; Taylor E; Gallivan J; Cawthorn GM; Vu D
    Can J Neurol Sci; 2011 Jul; 38(4):565-71. PubMed ID: 21672696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeted therapy and progressive multifocal leukoencephalopathy (PML): PML in the era of monoclonal antibody therapies].
    Takao M
    Brain Nerve; 2013 Nov; 65(11):1363-74. PubMed ID: 24200614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive multifocal leukoencephalopathy and newer biological agents.
    Berger JR
    Drug Saf; 2010 Nov; 33(11):969-83. PubMed ID: 20925435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
    Berger JR; Houff SA; Major EO
    MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive multifocal leukoencephalopathy.
    Weissert R
    J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of progressive multifocal leukoencephalopathy and natalizumab.
    Aksamit AJ
    Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
    Carson KR; Focosi D; Major EO; Petrini M; Richey EA; West DP; Bennett CL
    Lancet Oncol; 2009 Aug; 10(8):816-24. PubMed ID: 19647202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications.
    Greenlee JE
    Int MS J; 2006 Nov; 13(3):100-7. PubMed ID: 17101078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
    Werner MH; Huang D
    J Neurovirol; 2016 Dec; 22(6):871-875. PubMed ID: 27198748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
    Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.
    Tyler KL; Khalili K
    Rev Neurol Dis; 2005; 2(3):144-9. PubMed ID: 16400315
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Bacchetta F; Mathias A; Schluep M; Du Pasquier R
    Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.
    Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Hidalgo-Simon A; Egberts AC; Leufkens HG; De Bruin ML
    Clin Pharmacol Ther; 2015 Nov; 98(5):542-50. PubMed ID: 26347128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
    J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
    Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
    Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
    Warnke C; Menge T; Hartung HP; Racke MK; Cravens PD; Bennett JL; Frohman EM; Greenberg BM; Zamvil SS; Gold R; Hemmer B; Kieseier BC; Stüve O
    Arch Neurol; 2010 Aug; 67(8):923-30. PubMed ID: 20697042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
    Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.
    Piccinni C; Sacripanti C; Poluzzi E; Motola D; Magro L; Moretti U; Conforti A; Montanaro N
    Eur J Clin Pharmacol; 2010 Feb; 66(2):199-206. PubMed ID: 19838692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the management of PML: focus on natalizumab.
    Fox R
    Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.